3Vote!
Gauging Corporate Financial Results (Free subscription) | 25/11/2009
In a previous article , we examined Watson Pharmaceuticals ' ( NYSE: WPI ) Income Statement for the third quarter of 2009 and compared the entries on each line to our "look-ahead" estimates . Earnings in this period, which ended 30 September 2009, fell from $0.60 to $0.54 per share. [Note: our per-share numbers are slightly different than the official results because we don't adjust for interest...
3Vote!
iStockAnalyst.com (Free subscription) | 25/11/2009
In a previous article, we examined Watson Pharmaceuticals' (NYSE: WPI) Income Statement for the third quarter of 2009 and compared the entries on each line to our "look-ahead" estimates. [More...]
3Vote!
Fiercebiotech (Free subscription) | 18/11/2009
Peter Thompson , Trubion Pharmaceuticals' president, CEO, chairman of the board and co-founder, has retired. Steven Gillis , former lead director of Trubion's board, has been appointed executive chairman of the board and acting president. Michelle Burris , Trubion's senior vice president and chief financial officer, will assume the role of chief operating officer, and John Bencich , the company's...
Explore : AstraZeneca,
Bausch and Lomb,
Biology,
Channels,
Discovery,
Drug Manufacturers,
Eli Lilly,
Generic Drugs,
Health Industries,
Medical Products and Supplies,
Merck
3Vote!
PR News Wire (Free subscription) | 16/11/2009
MORRISTOWN, N.J., Nov. 16 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals (NYSE: WPI) today announced that Robert A. Stewart has joined the Company in the newly created position of Senior Vice President, Global Operations, effective immediately. In this position, Mr. Stewart will have responsibility for global manufacturing, supply chain, quality and technical operations.
3Vote!
The Earth Times Online Newspaper (Free subscription) | 11/11/2009
MORRISTOWN, N.J., Nov. 10 -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today a change for the Company's presentation at the Credit Suisse 18th Annual Healthcare Conference scheduled for Wednesday, November ...
3Vote!
PR News Wire (Free subscription) | 11/11/2009
MORRISTOWN, N.J., Nov. 10 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today a change for the Company's presentation at the Credit Suisse 18th Annual Healthcare Conference scheduled for Wednesday, November 11, 2009. Watson's presentation will take place at 11:00 a.m. Eastern Standard Time.
3Vote!
SeekingAlpha.com (Free subscription) | 08/11/2009
Neil Carvin submits: Watson Pharmaceuticals, Inc. ( WPI ) earned $0.54 per share in the third quarter of 2009, down from $0.60 in the same quarter of last year. [Note: our per-share numbers are slightly different than the official results because we don't adjust for interest expenses on convertible contingent senior debentures (CODES).] This post examines the Income Statement for the quarter in the...
3Vote!
CFO (Free subscription) | 06/11/2009
WebMD Health, CVS Caremark, The Greater Boston Food Bank, Hallador Petroleum, Codexis, Deluxe, Lydall, Diebold, Watson Pharmaceuticals, Cymer.
Explore : Computer industry,
CVS,
Cymer,
Diebold,
Drug Manufacturers,
Equipment,
Generic Drugs,
Health Industries,
Office Supplies and Equipment,
Semi-Conductors,
Software,
Software and services,
WebMD Health
3Vote!
US News & World Report (Free subscription) | 04/11/2009
Watson Pharmaceuticals, Inc. (NYSE: WPI) third-quarter net income fell to $63 million, or 55 cents a share and on an adjusted basis, earnings in the latest quarter were 66 cents a share. While its net revenue rose to $662 million from $641 million versus Analysts estimations of 64 cents a share on sales of $688 [...]
3Vote!
Market Watch (Free subscription) | 04/11/2009
NEW YORK (MarketWatch) -- Watson Pharmaceuticals Inc. said Wednesday that its third-quarter net income fell to $63 million, or 55 cents a share, from $71 million, or 62 cents a share, in the year-earlier period. On an adjusted basis, earnings in the latest quarter were 66 cents a share. The pharmaceutical company said net revenue rose to $662 million from $641 million. Analysts polled by FactSet had...
Videos